Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tumor cell vaccine + GM.CD40L + interleukin-2
- Development stage
- Unknown
- Lead developer
- Moffitt Cancer Center
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intradermal, Subcutaneous
01
Overview
This combination immunotherapy protocol, developed by the H. Lee Moffitt Cancer Center and Research Institute, is designed for the treatment of mantle cell lymphoma (MCL). The regimen involves an autologous tumor cell vaccine formulated with a universal bystander cell line (GM.CD40L) that has been genetically engineered to secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and express CD40 Ligand (CD40L). This vaccine is administered alongside low-dose interleukin-2 (IL-2). The mechanism of action relies on the GM.CD40L cells to activate host dendritic cells and enhance the presentation of tumor antigens derived from the patient's own harvested MCL cells. Simultaneously, IL-2 acts as a cytokine support to promote the expansion and effector function of tumor-specific T-cells. This therapeutic approach is typically employed as a consolidation strategy following induction chemotherapy to eradicate residual disease and prolong remission in patients with MCL.
- Other names
- GM.CD40L vaccine + IL-2autologous tumor cell-based vaccine with GM.CD40L and IL-2
Beyond the preview
Go deeper on autologous tumor cell vaccine + GM.CD40L + interleukin-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tumor cell vaccine + GM.CD40L + interleukin-2.